19-28ζ CAR T-Cells Induce High CR Rate in Relapsed/Refractory Adult ALL

May 29-June 2, 2015; Chicago, Illinois
CD19-targeted 19-28ζ CAR T-cell therapy produced a high CR rate in adult patients with relapsed/refractory ALL.
Format: Microsoft PowerPoint (.ppt)
File Size: 362 KB
Released: June 5, 2015

Acknowledgements

Educational grant provided by:
AstraZeneca
Bayer Healthcare Pharmaceuticals, Inc.
Bristol-Myers Squibb
Celgene Corporation
Genentech BioOncology
Incyte
Novartis Pharmaceuticals Corporation

Related Content

Downloadable slides with expert insights on the latest therapeutic agents to treat acute myeloid leukemia from Clinical Care Options.

Stéphane de Botton, MD Released: July 10, 2020

Downloadable summary slideset of key takeaways from a live CCO Webinar focused on the optimal use of BTK inhibitors in patients with CLL.

Danielle Brander, MD Nicole Lamanna, MD Jeff P. Sharman, MD Released: July 10, 2020

In this slideset from Clinical Care Options (CCO), experts provide insights into best practices in testing for NTRK fusions in solid tumors

George D. Demetri, MD Released: July 10, 2020

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of TRK inhibitor therapy for solid tumors

Pashtoon Kasi, MD Released: July 10, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?